on BIOSYNEX (EPA:ALBIO)
BIOSYNEX announces a decline in revenue for the first half of 2025
BIOSYNEX SA reported revenue of €50.8 million for the first half of 2025, a 6% decrease compared to the same period in 2024. This decrease is attributed to the effects of the disposal of BIOSYNEX Technologies GmbH and the end of certain pharmacy inventories. The Diagnostics division also recorded a 6% decrease, impacted by changes in test coverage in France.
Despite this decline, the company anticipates an improvement in its EBITDA thanks to restructuring and more precise market selection. Numerous product launches are planned for the second half of the year, particularly in partnership with the UNIVERSAL® group.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news